Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Reilly

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Cancer Research|September 10, 2009
Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancerWeisheng Zhang, Joe Zhu, Clay L Efferson, et al.
Experimental Hematology & Oncology|November 22, 2014
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trialTeresa Moran, Enriqueta Felip, Vicki Keedy, et al.
ACS Medicinal Chemistry Letters|November 22, 2019
Discovery of a Potent and Selective TRPC5 Inhibitor, Efficacious in a Focal Segmental Glomerulosclerosis ModelMaolin Yu, Mark W Ledeboer, Matthew Daniels, et al.
Kidney International Reports|October 8, 2021
Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial DesignLiron Walsh, John F Reilly, Caitlin Cornwall, et al.
Cancer Research|November 12, 2009
De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor modelJames W Watters, Chun Cheng, Pradip K Majumder, et al.
Cancer Research|March 4, 2010
Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer modelClay L Efferson, Christopher T Winkelmann, Christopher Ware, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 9, 2005
Adult mouse brain gene expression patterns bear an embryologic imprintMatthew A Zapala, Iiris Hovatta, Julie A Ellison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2009
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group studyEvanthia Galanis, Kurt A Jaeckle, Matthew J Maurer, et al.
Cancer Research|May 17, 2008
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphomaValeria R Fantin, Andrey Loboda, Cloud P Paweletz, et al.
Journal of Molecular Biology|January 23, 2023
Phase Separation in Biology and Disease; Current Perspectives and Open QuestionsSteven Boeynaems, Shasha Chong, Jörg Gsponer, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Cancer Research|September 10, 2009
Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancerWeisheng Zhang, Joe Zhu, Clay L Efferson, et al.
Experimental Hematology & Oncology|November 22, 2014
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trialTeresa Moran, Enriqueta Felip, Vicki Keedy, et al.
ACS Medicinal Chemistry Letters|November 22, 2019
Discovery of a Potent and Selective TRPC5 Inhibitor, Efficacious in a Focal Segmental Glomerulosclerosis ModelMaolin Yu, Mark W Ledeboer, Matthew Daniels, et al.
Kidney International Reports|October 8, 2021
Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial DesignLiron Walsh, John F Reilly, Caitlin Cornwall, et al.
Cancer Research|November 12, 2009
De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor modelJames W Watters, Chun Cheng, Pradip K Majumder, et al.
Cancer Research|March 4, 2010
Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer modelClay L Efferson, Christopher T Winkelmann, Christopher Ware, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 9, 2005
Adult mouse brain gene expression patterns bear an embryologic imprintMatthew A Zapala, Iiris Hovatta, Julie A Ellison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2009
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group studyEvanthia Galanis, Kurt A Jaeckle, Matthew J Maurer, et al.
Cancer Research|May 17, 2008
Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphomaValeria R Fantin, Andrey Loboda, Cloud P Paweletz, et al.
Journal of Molecular Biology|January 23, 2023
Phase Separation in Biology and Disease; Current Perspectives and Open QuestionsSteven Boeynaems, Shasha Chong, Jörg Gsponer, et al.
Pageof 3